EQS-News

Relief and AdVita Sign Binding Term Sheet for Relief to Acquire All Shares of AdVita to Expand Scope of Development of Inhaled Formulation of Aviptadil - Seite 3

CONTACT RELIEF THERAPEUTICS Holding AG Raghuram (Ram) Selvaraju, Ph.D., MBA                   Chairman of the Board Mail: [e-mail] www.relieftherapeutics.com AdVita Lifescience GmbH Wolfgang Hoppe Chief Executive Officer [e-mail] www.advita-lifescience.com

FOR MEDIA/INVESTOR INQUIRES: MC Services AG Anne Hennecke / Brittney Sojeva Mail: [e-mail] Tel.: [phone]

 

Disclaimer: This communication expressly or implicitly contains certain forward-looking statements concerning RELIEF THERAPEUTICS Holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of RELIEF THERAPEUTICS Holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. RELIEF THERAPEUTICS Holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

---

End of Media Release

---

Language:	English
Company:	RELIEF THERAPEUTICS Holdings AG
	Avenue de Sécheron 15
	1202 Genève
	Switzerland
E-mail:	[e-mail]
Internet:	https://relieftherapeutics.com
ISIN:	CH0100191136
Listed:	SIX Swiss Exchange
EQS News ID:	1161800